Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: scambia g. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A, Duranti S, Daniele G, Nero C, Ciccarone F, Lorusso D, Fagotti A, Scambia G. Pietragalla A, et al. Among authors: scambia g. Expert Opin Investig Drugs. 2021 Feb;30(2):103-110. doi: 10.1080/13543784.2021.1868436. Epub 2021 Jan 11. Expert Opin Investig Drugs. 2021. PMID: 33423551 Review.
Immunotherapy in gynecological cancers.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: scambia g. Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046088 Free PMC article. Review.
Integration of PARP-inhibitors in ovarian cancer therapy.
Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G. Pietragalla A, et al. Among authors: scambia g. Explor Target Antitumor Ther. 2020;1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29. Explor Target Antitumor Ther. 2020. PMID: 36046198 Free PMC article. Review.
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Carbognin L, Accetta C, Di Giorgio D, Fuso P, Muratore M, Tiberi G, Pavese F, D'Angelo T, Fabi A, Giannarelli D, Di Leone A, Magno S, Garganese G, Sanchez AM, Terribile DA, Franceschini G, Masetti R, Scambia G, Paris I. Carbognin L, et al. Among authors: scambia g. Curr Oncol. 2022 Sep 30;29(10):7218-7228. doi: 10.3390/curroncol29100569. Curr Oncol. 2022. PMID: 36290846 Free PMC article.
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting.
Franco A, Di Leone A, Fabi A, Belli P, Carbognin L, Gambaro E, Marazzi F, Mason EJ, Mulè A, Orlandi A, Palazzo A, Paris I, Rossi A, Scardina L, Terribile DA, Tiberi G, Giannarelli D, Scambia G, Masetti R, Franceschini G. Franco A, et al. Among authors: scambia g. Cancers (Basel). 2023 Apr 25;15(9):2450. doi: 10.3390/cancers15092450. Cancers (Basel). 2023. PMID: 37173916 Free PMC article.
1,968 results